This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01303/identifier/chemspider/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01303/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01303/identifier/pharmgkb/
n16http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01303/identifier/pubchem-compound/
n13http://www.drugs.com/mtm/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01303/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB01303/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01303/identifier/drugbank/
n3http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01303
rdf:type
n3:Drug
n3:description
Oxtriphylline is the choline salt form of theophylline. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse is to dilate the bronchioles. As such, oxytriphylline is indicated mainly for asthma, bronchospasm, and COPD (i.e. all the same indications as the other theophyllines). It is marketed under the name Choledyl SA, and several forms of oxytriphylline have been discontinued. In the US, oxtriphylline is no longer available.
n3:group
approved
n3:halfLife
The serum half life varies greatly between patients and in age. The half life range for a healthy, nonsmoking adult is 3-12.8 hours, for children is 1.5–9.5 hours, and for for premature infants is 15–58 hours.
n3:indication
Used to treat the symptoms of asthma, bronchitis, COPD, and emphysema.
owl:sameAs
n16:DB01303 n23:DB01303
dcterms:title
Oxtriphylline
adms:identifier
n8:Oxtriphylline n9:PA164748137 n19:46507376 n20:D02017 n21:656652 n22:571001 n24:DB01303
n3:mechanismOfAction
Oxtriphylline is a choline salt of theophylline. After ingestion, theophylline is released from oxytriphylline, and theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.
n3:packager
n4:271B6470-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The kidneys are the main route of elimination for both theophylline and its metabolites, but some unchanged theophylline is eliminated in the feces.
n3:synonym
Theophyline - choline mixt Choline theophylline Theocolin Oxtriphylline Choline theophyllinate
n3:toxicity
Symptoms of toxicity include abdominal pain (continuing or severe), confusion or change in behavior, convulsions (seizures), dark or bloody vomit, diarrhea, dizziness or lightheadedness, fast and/or irregular heartbeat, nervousness or restlessness (continuing), and trembling (continuing).
n3:volumeOfDistribution
Theophylline has an apparent volume of distribution of 0.3–0.7 L/kg in children and adults, and the Vd is about twice that of an adult in premature infants.
n10:hasAHFSCode
n25:86-16-00
n3:foodInteraction
Avoid high doses of caffeine. Take with food to reduce irritation.
n3:proteinBinding
With a serum concentrations of 17 mcg/mL, adults and children have about 56% theophylline bound to plasma protein, and premature infants have about 36%.
n3:synthesisReference
Ladenburg, K., Duesel, B.F. and Fand,T.I.; U S . Patent 2,776,287; January 1,1957; assigned to Nepera Chemical Co., Inc.
n17:hasConcept
n18:M0060158
foaf:page
n13:oxtriphylline.html
n3:IUPAC-Name
n5:271B6477-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B647D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B647C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B6479-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B647A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B647B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B648D-363D-11E5-9242-09173F13E4C5 n5:271B6475-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B6473-363D-11E5-9242-09173F13E4C5 n5:271B6476-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B6474-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:R03DA02
n3:H-Bond-Acceptor-Count
n5:271B6483-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B6484-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B647E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B647F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B6481-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B6480-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B6482-363D-11E5-9242-09173F13E4C5
n3:absorption
After ingestion, theophylline is released from oxytriphylline in the acidic environment of the stomach.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
4499-40-5
n3:category
n3:clearance
Theophylline has an average clearance in children (over 6 months) of 1.45 mL/kg per minute, and in healthy, nonsmoking adults of 0.65 mL/kg per hour.
n3:containedIn
n6:271B6471-363D-11E5-9242-09173F13E4C5 n6:271B6472-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B6489-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B648B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B648C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B6488-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B6487-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B648A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B6478-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B6485-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B6486-363D-11E5-9242-09173F13E4C5